We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Plasmodium vivax Isolated in Duffy Negative Individuals

By LabMedica International staff writers
Posted on 12 Dec 2018
Malaria in Nigeria is principally due to Plasmodium falciparum and, to a lesser extent to P. More...
malariae and P. ovale. P. vivax is thought to be absent in Nigeria in particular and sub-Saharan Africa in general, due to the near fixation of the Duffy negative gene in this population.

Microscopy which is the gold standard for malaria diagnosis can detect Plasmodium infections in individuals with high level of parasitaemia; however parasite detection in individuals carrying low parasite density can be challenging, thus emphasizing the need for more sensitive diagnostic methods.

Medical parasitologists at the Université Cheikh Anta Diop (Dakar, Senegal) carried out a cross-sectional investigation involving 436 febrile patients were included for the present work patients presenting clinical symptoms of malaria and visiting any of the various hospitals in two study sites between September 2016 to March 2017. Venous blood of these patients was subjected to a P. falciparum specific HRP2 rapid diagnostic test, as well as microscopy.

Parasite DNA was isolated from positive samples and polymerase chain reaction (PCR) diagnostic was employed followed by direct sequencing of the 18S rRNA of Plasmodium species as well as sequencing of a portion of the promoter region of the Duffy antigen receptor for chemokines. Samples positive for P. vivax were re-amplified several times and finally using the High Fidelity Taq to rule out any bias introduced. In order to validate the different species identified by PCR in gel electrophoresis, the 18S rRNA gene of P. vivax and the DARC-coding gene of the P. vivax infected individuals were sequenced commercially by Inqaba Biotec.

The team reported that of the 256 (58.7%) amplifiable malaria parasite DNA, P. falciparum was, as expected, the major cause of infection, either alone 85.5% (219/256), or mixed with P. malariae 6.3% (16/256) or with P. vivax 1.6% (4/256). Only one of the five P. vivax isolates was found to be a single infection. DNA sequencing and subsequent alignment of the 18S rRNA of P. vivax with the reference strains displayed very high similarities (100%). Remarkably, the T-33C mutation was identified in all P. vivax samples, thus confirming that all vivax-infected patients in the current study are Duffy negative.

The authors concluded that given the fact that Nigeria accounts for 27% of the global malaria burden mostly due to P. falciparum, the addition of P. vivax to this, will ultimately add to the burden of country’s struggle to control malaria and the defensive barrier hypothesis against P. vivax infection due to the near fixation of the Duffy-negative gene in the African population should be investigated. The study was published on November 28, 2018, in the Malaria Journal.

Related Links:
Université Cheikh Anta Diop


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.